SOURCE: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals, Inc.

September 17, 2014 11:31 ET

PetLife Publishes Two White Papers on History and Production of Escozine for Pets™

BEVERLY HILLS, CA--(Marketwired - Sep 17, 2014) - PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has published two white papers that explain the science underlying Escozine for Pets™. The first of which is History of Escozine For Pets, and the second is Stages of Production of Escozine For Pets which contains a highly detailed and scientifically technical analysis of the production and polarization process from start to finish.

Both are available on the Company's website at:

PetLife plans to publish its next white paper on the zoological, biological and biotech science of scorpions, featuring its unique Blue Scorpion Reservation on twelve acres in the Dominican Republic containing over 40,000 Blue Scorpions.

Highlights of History of Escozine for Pets White Paper:

  • PetLife Pharmaceuticals and its sister company, Medolife, are the only companies in the world with the patented Escozine formulation based upon Blue Scorpion Venom. Escozine For Pets™ is solely owned and commercialized by PetLife Pharmaceuticals.
  • PetLife Founder and CEO Arthur Mikaelian, Ph.D. is the scientist who completed the R&D and attained the legal registration to commercialize the Blue Scorpion venom-based product under the name of Escozine For Pets. 
  • Escozine and Escozine for Pets utilize the licensed, patented polarization technology which produces a far more effective product than Labiofams's Blue Scorpion venom in Escozul and Vidatox.
  • PetLife, in affiliation with Medolife, has its own independent source of Blue Scorpion venom in the Dominican Republic, the world's first Scorpion reservation of 50,000 square meters that can produce millions of doses to meet global demand.
  • The world renowned Atheris Laboratory in Switzerland has provided scientific confirmation to Medolife that Blue Scorpion venom blocks sodium and potassium volt gate channels. This action causes actual shrinkage of tumors and inhibits cancer cell proliferation.
  • The report indicates that Dominican Blue Scorpion venom has a three times higher concentration of Chlorotoxin (CLTX) -- which is one of the main components with anti-tumoral properties and also has smaller molecular weight -- than the Cuban blue scorpion venom. This high concentration of CLTX makes Escozine For Pets™ more effective in the penetration of cancer cell membranes as well as the blood-brain barrier.

Highlights of Stages of Production of Escozine for Pets White Paper:

  • A highly detailed and scientifically technical analysis of the production and polarization process from start to finish.
  • The Blue Scorpions are collected from PetLife's unique Scorpion Reservation located in the Dominican Republic. The reservation is highly organized with professional staff taking care of the scorpions' population. PetLife has the ability to produce millions of bottles of Escozine For Pets™ monthly.
  • Scorpions are collected and delivered to a laboratory where they undergo the venom extraction process. The process does not harm the scorpions, which are later returned to their habitat. After the venom is collected, it goes through centrifugation, filtration, and therapeutic dose preparation.
  • At this point the concentration has been prepared for polarization. Specialists handle the concentration and run it through the patented polarization machine, which increases the concentrate's potency.
  • In its US FDA approved production facility, PetLife's product manufacturer in Commerce, California receives the purified and concentrated venom where it is undergoes a microbiology test prior to production. It is then mixed and bottled into sterilized bottles that are closed and sealed with plastic shrink neck bands.
  • Some of the bottles in each batch are selected for quality control and have a microbiology test, and then the rest are packed into cases for shipment. PetLife employees supervise the shipment and handling of all orders to ensure that the packaging and boxing meets the highest standards.

About Petlife Pharmaceuticals
PetLife ( is a registered US Veterinary Pharmaceutical company, incorporated in 2012, and a spinoff of Medolife Corp.

PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets -- Escozine for Pets™. It is based on the same patented 'Escozine for humans' formula that has been sold by affiliate Medolife in 40 countries, using a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.

PetLife's mission is to bring its new, scientifically proven, non-toxic, high potency bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer, extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals is expected to reach over $58 billion in 2014 with over $13 billion being spent on over the counter medications.

Safe Harbor Statement
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at Statements released by PetLife that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. The company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The company does not undertake any responsibility to update the forward-looking statements contained in this release.

Contact Information